The present invention provides compounds of the Formula I below
where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
[EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
申请人:LILLY CO ELI
公开号:WO2021118877A1
公开(公告)日:2021-06-17
The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
[EN] QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF<br/>[FR] COMPOSÉS DE QUINAZOLINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
申请人:INVENTISBIO CO LTD
公开号:WO2022002102A1
公开(公告)日:2022-01-06
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.
[EN] HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
申请人:INVENTISBIO CO LTD
公开号:WO2022042630A1
公开(公告)日:2022-03-03
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.